Ewing Sarcoma Clinical Trials in Washington D.C., District of Columbia

3 studies are recruiting for ewing sarcoma in Washington D.C., District of Columbia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

    This is a phase I dose-escalation study to determine the safety and feasibility of autologous CAR-TA T cells (B7-H3 CAR+ T cells administered with DNR-PRAME Tumor Antigen-specific T cells) following lymphodepleting chemotherapy in participants with relapsed/refractory rhabdomyosarcoma, Ewing sarcom…

    Stage
    Phase 1
    Ages
    1 to 23
    Site
    Children's National Hospital, Washington D.C., District of Columbia
    Locations
    2 in total
    Run by
    Children's National Research Institute

    See if you can join NCT07172958 on ClinicalTrials.gov

  2. Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma

    This study is designed for children, adolescents and young adults undergoing radiation therapy for metastatic sarcoma. The aim of the study is to investigate if the investigators can improve the overall survival of these patients by targeting metastatic sites with radiation.

    Stage
    Not phased
    Ages
    Up to 39
    Site
    Sibley Memorial Hospital, Washington D.C., District of Columbia
    Locations
    3 in total
    Run by
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    See if you can join NCT06796543 on ClinicalTrials.gov

  3. Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

    This study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric participants with previously treated solid tumors. This is followed by the …

    Stage
    Phase 1
    Ages
    2 to 30
    Site
    Children's National Hospital, Washington D.C., District of Columbia
    Locations
    15 in total
    Run by
    Jazz Pharmaceuticals

    See if you can join NCT05734066 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.